Gaudium IVF and Women Health’s IPO of Equity Shares to open on February 20, 2026

• Price Band is fixed at ₹75 to ₹79 per Equity Share of face value of ₹ 5 each (“Equity Share”).
• The Anchor Investor Bidding Date will open and close on Thursday, February 19, 2026.
• The Offer opens on Friday, February 20, 2026, for Bids and closes on Tuesday, February 24, 2026.
• Bids can be made for a minimum of 189 Equity Shares and in multiples of 189 Equity Shares thereafter.

 RHP Link: https://www.sarthi.in/wp-content/uploads/2026/02/Gaudium_RHP.pdf

Ahmedabad, February 18, 2026: Gaudium IVF and Women Health Limited (“Gaudium IVF” or “The Company”), announces that the Bid / Offer Opening Date in relation to its initial public offer of the Equity Shares (“Offer”) will be Friday, February 20, 2026.

The Offer comprises a fresh issue of such number of Equity Shares by the Company aggregating up to 1,13,92,500 Equity Shares (the “Fresh Issue”) and an offer for sale of up to 94,93,700 Equity Shares (the “Offer for Sale”) by Dr. Manika Khanna, promoter selling shareholder (the “Selling Shareholder”).

The Company proposes to utilise the Net Proceeds towards Funding capital expenditure towards establishment of New IVF Centers of the Company, Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company, and general corporate purposes (the “Objects of the Offer”).

The Anchor Investor Bid/Offer Period opens and closes on Thursday, February 19, 2026. The Bid/Offer Period will open on Friday, February 20, 2026 for subscription and close on Tuesday, February 24, 2026.

The Price Band of the Offer has been fixed at ₹75 to ₹79 per Equity Share. Bids can be made for a minimum of 189 Equity Shares and in multiples of 189 Equity Shares thereafter. This Equity Shares are being offered through the RHP.

The Equity Shares to be offered through the RHP are proposed to be listed on the Main Board of BSE Limited and National Stock Exchange of India Limited (“NSE”). For the purposes of the Offer, NSE is the Designated Stock Exchange. Sarthi Capital Advisors Private Limited is the sole Book Running Lead Manager to the Offer (the “BRLM”).

All capitalised terms used herein but not defined shall have the same meaning as ascribed to them in the RHP. This is an Offer in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in terms of Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs and such portion, the “QIB Portion”), provided that our Company, in consultation with the BRLM, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”), of which 40% of the Anchor Investor Portion shall be reserved in the following manner (i) 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds; and (ii) 6.67% of the Anchor Investor Portion shall be reserved for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds, as applicable, at or above the Anchor Investor Allocation Price. Any under-subscription in the Life Insurance Companies and Pension Funds category specified in (ii) above may be allocated to domestic Mutual Funds, in accordance with the SEBI ICDR Regulations. In the event of under-subscription in the Anchor Investor Portion, the remaining Equity Shares shall be added to the Net QIB Portion.

Further, 5% of the QIB Portion (excluding Anchor Investor portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion (excluding Anchor Investor Portion) shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Issue Price. In the event the aggregate demand from Mutual Funds is less than as specified above, the balance Equity Shares available for Allotment in the Mutual Fund Portion will be added to the QIB Portion and allocated proportionately to the QIB Bidders (other than Anchor Investors) in proportion to their Bids.

Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders of which one-third portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 2 lakhs and up to ₹ 10 lakhs and two-third portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 10 lakhs, provided that unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders in accordance with the SEBI ICDR Regulations and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are mandatorily required to utilize the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA accounts and UPI ID in case of UPI  Bidders using  the  UPI Mechanism,  as  applicable,  pursuant  to  which  their  corresponding  Bid  Amount  will  be  blocked  by  the  Self  Certified Syndicate Banks (“SCSBs”) or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA Process. For further details, see “Offer Procedure” on page 379.

Disclaimer:  Gaudium IVF and Women Health Limited is proposing, subject to, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with the RoC on February 13, 2026. The RHP is available on the website of the Company at www.gaudiumivfcentre.com, SEBI at www.sebi.gov. in, as well as on the website of the BRLM Sarthi Capital Advisors Private Limited at www.sarthi.in, and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see “Risk Factors” on page 31 of the RHP. Potential investors should not rely on the DRHP for making any investment decision and instead should place reliance on the RHP. Specific attention of the investors is invited to “Risk Factors” beginning on page 31 of the RHP.

 This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the“U.S. Securities Act”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) in the United States only to  “qualified institutional buyers”, as defined in Rule 144A under the U.S. Securities Act, in transactions exempt from the registration requirements of the U.S. Securities Act and (ii) outside the United States in “offshore transactions” as defined in, and in reliance on Regulation S under the U.S. Securities Act and in accordance with the applicable laws of the jurisdictions where such offers and sales are made. There will be no public offering of the Equity Shares in the United States.